Edition:
India

Emergent BioSolutions Inc (EBS.N)

EBS.N on New York Stock Exchange

66.16USD
15 Feb 2019
Change (% chg)

$1.15 (+1.77%)
Prev Close
$65.01
Open
$65.14
Day's High
$66.50
Day's Low
$65.14
Volume
110,906
Avg. Vol
125,365
52-wk High
$73.83
52-wk Low
$46.51

Select another date:

Tue, Nov 20 2018

Emergent-Valneva Zika vaccine clears early trial

A vaccine to prevent infections caused by the deadly mosquito-borne Zika virus induced immune response and was found to be safe in an early stage trial, Emergent BioSolutions Inc and partner Valneva SE said on Monday.

Emergent-Valneva Zika vaccine clears early trial

Nov 19 A vaccine to prevent infections caused by the deadly mosquito-borne Zika virus induced immune response and was found to be safe in an early stage trial, Emergent BioSolutions Inc and partner Valneva SE said on Monday.

Emergent BioSolutions to buy Narcan maker Adapt Pharma

Emergent BioSolutions Inc said on Tuesday it would buy privately held Adapt Pharma, beefing up its portfolio with Narcan, the only FDA approved needle-free emergency opioid overdose treatment.

Emergent BioSolutions to buy Narcan maker Adapt Pharma

Emergent BioSolutions Inc said on Tuesday it would buy privately held Adapt Pharma, beefing up its portfolio with Narcan, the only FDA approved needle-free emergency opioid overdose treatment.

UPDATE 2-Emergent BioSolutions to buy Narcan maker Adapt Pharma

* Adapt partner Opiant soars in after-hours trading (Adds details and comment from conference call)

Emergent BioSolutions to buy Adapt Pharma for up to $735 mln

Aug 28 Emergent BioSolutions Inc said on Tuesday it would buy privately held Adapt Pharma for up to $735 million to acquire its drug Narcan, the only needle-free emergency treatment approved to treat opioid overdose.

Select another date: